ADMA Biologics to Present at the 2015 Marcum MicroCap Conference
23 May 2015 - 7:17AM
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical
company that develops, manufactures, and intends to market
specialty plasma-based biologics for the treatment and prevention
of certain infectious diseases, announced that it will present at
the 2015 Marcum MicroCap Conference on May 28, 2015 in New York
City at the Grand Hyatt New York.
Adam Grossman, President and Chief Executive Officer will
provide a corporate overview, which is scheduled for 9:00 AM ET. A
live webcast may be accessed under the "Investor Relations" tab on
the Company's website at www.admabiologics.com. A replay of the
webcast will be available after the conclusion of the live
event.
About ADMA Biologics, Inc. ADMA is a late stage
biopharmaceutical company that develops, manufactures, and intends
to market specialty plasma-based biologics for the treatment and
prevention of certain infectious diseases. ADMA's mission is to
develop and commercialize plasma-derived, human immune globulins
targeted to niche patient populations for the treatment and
prevention of certain infectious diseases. The target patient
populations include immune-compromised individuals who suffer from
an underlying immune deficiency disease or who may be
immune-compromised for medical reasons. For more information,
please visit the Company's website at www.admabiologics.com.
About ADMA's lead product candidate RI-002:
ADMA's lead product candidate, RI-002 is a specialty
plasma-derived, polyclonal, Intravenous Immune Globulin, or IGIV,
derived from human plasma containing naturally occurring polyclonal
antibodies (e.g., Streptococcus pneumoniae, H. influenza type B,
Cytomegalovirus (CMV), measles, tetanus, etc.) as well as
standardized, high levels of antibodies to respiratory syncytial
virus (RSV). ADMA is pursuing an indication for the use of this
specialty IGIV product for treatment of patients diagnosed with
primary immune deficiency diseases, or PIDD. Polyclonal antibodies
are the primary active component of IGIV products. Polyclonal
antibodies are proteins that are used by the body's immune system
to neutralize microbes, such as bacteria and viruses. Data review
indicates that the polyclonal antibodies that are present in RI-002
support the ability of this product to prevent infections in
immune-compromised patients. ADMA's analysis demonstrated that the
Phase III trial has met the primary endpoint with no serious
bacterial infections (SBI) reported. These results are below the
requirement specified by FDA guidance of ≤ 1 SBI per
patient-year.
Forward-Looking Statements
This press release contains "forward looking statements"
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or
achievements, and may contain the words "estimate," "project,"
"intend," "forecast," "target," "anticipate," "plan," "planning,"
"expect," "believe," "will," "will likely," "is likely", "should,"
"could," "would," "may" or, in each case, their negative, or words
or expressions of similar meaning. These forward-looking statements
include, but are not limited to, statements concerning
interpretations of final data, possible characteristics of RI-002,
acceptability of RI-002 for any purpose by physicians patients or
payers, timing and ability of a filing with the FDA of a BLA,
likelihood and timing of FDA action with respect to any further
filings by the Company, results of the clinical development,
continuing demonstrations of safety, comparability of results of
RI-002 to other comparably run IVIG trials, improvements in
clinical outcomes, market data and incidence of infection,
regulatory processes, potential clinical trial initiations,
potential investigational new product applications, biologics
license applications, expansion plans, the achievement of clinical
and regulatory milestones, commercialization efforts of the
Company's product candidate(s) and trends relating to demand for
source plasma. Forward-looking statements are subject to many risks
and uncertainties that could cause our actual results and the
timing of certain events to differ materially from any future
results expressed or implied by the forward-looking statements,
including, but not limited to, risks as to whether final and
secondary data will be accepted as encouraging, positive or will
otherwise lead to an effective or approved product, whether we will
be able to demonstrate efficacy or gain necessary approvals to
market and commercialize any product, whether the FDA will accept
our data, permit us to submit a BLA, grant a license, or approve
RI-002 for marketing, whether we will meet any of our clinical or
regulatory milestones, whether we will develop any new products or
expand existing ones, whether we will receive FDA approval of our
new facility, whether there may be changes in regional and
worldwide supply and demand for source plasma, whether we will be
able to attract sufficient donors and operate our new facility
effectively or profitably, whether we can sell our plasma in the
marketplace at prices that will lead to adequate amounts of
revenue, whether we will be able to sustain the listing of our
common stock on the NASDAQ Capital Market, whether we will meet any
timing targets expressed by the Company, and other risks and
uncertainties described in our filings with the U.S. Securities and
Exchange Commission, including our most recent reports on Forms
10-K, 10-Q and 8-K, and any amendments thereto. Therefore,
current and prospective security holders are cautioned that there
also can be no assurance that the forward-looking statements
included in this press release will prove to be accurate. In light
of the significant uncertainties inherent to the forward-looking
statements included herein, the inclusion of such information
should not be regarded as a representation or warranty by ADMA or
any other person that the objectives and plans of ADMA will be
achieved in any specified time frame, if at all. Except to the
extent required by applicable laws or rules, ADMA does not
undertake any obligation to update any forward looking statements
or to announce revisions to any of the forward-looking
statements.
CONTACT: Brian Lenz
Vice President and Chief Financial Officer | 201-478-5552 | www.admabiologics.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024